Hepatitis C virus infection in the human immunodeficiency virus infected patient

Table 1 Interferon-free clinical trials conducted in human immunodeficiency virus - hepatitis C virus coinfected individuals

Direct acting antiviral			Ribavirin	Study name/identifier1	Patient population	Phase	Primary endpoint	Presented results
Ns3/4a protease inhibitor	Ns5b polymerase inhibitors	Ns5a inhibitors
No	Sofosbuvir	No	Yes	Photon-I (Ncto1667731)	GT 1:	3	SVR 12	GT 1: 76%2
					TN and IFN ineligible			GT 2: 88%
					GT 2 + 3: TE			GT 3: 67%
No	Sofosbuvir	No	Yes	Ncto1783678	GT 1 + 2 + 3 + 4:	3	SVR 12	No
					TN and IFN ineligible
					GT 2 + 3: TE
ABT-450(r)	ABT-333	ABT-267	Yes	Turquoise I (Ncto1939197)	GT 1	3	SVR 12	No
					TN + TE
MK-5172	No	MK-8742	Yes	c-WORHTy (Ncto01717326)	GT 1	2	SVR 12	No

¹ClinicalTrials.gov;

²Preliminary data presented at the Conference on Retroviruses And Opportunistic Infections, 2014. GT: Hepatitis C virus genotype; TN: Treatment naive; IFN: Interferon; TE: Treatment experienced; SVR: Sustained virological response; r: Ritonavir boosted.